PILA PHARMA: ALL INVESTOR PRESENTATION RECORDINGS NOW ONLINE
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA VISITED DIREKT STUDIOS' INVESTMENT CHANNEL
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today informs inv...
PILA PHARMA PARTICIPATED IN INVESTMENT PODCAST 10X
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, hereby invites in...
PILA PHARMA UPCOMING INVESTOR PRESENTATIONS IN STOCKHOLM
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, hereby invites in...
PILA PHARMA DISCUSSED ITS POTENTIAL ROLE IN OBESITY & DIABETES WITH HELGE LARSEN & PROINVESTOR
PILA PHARMA AB (publ) (FN STO: PILA) has the pleasure to share with investors and others with interest in the Company or the general market, that PILA PHARMA had a 1-on-1 intervi...
PILA PHARMA TO RE-VISIT PROINVESTOR WITH HELGE LARSEN TO DISCUSS THE COMPANY'S AMBITIONS IN OBESITY & DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) today informs investors and others with interest in the Company, that PILA PHARMA will be going back to participate for a 1-on-1 interview wi...
REG
MAR
PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) today informs the continuation of preparations for the clinical trial application for PP-CT03, a pivotal and pioneering 12-week Phase 2a stud...
REG
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025
PILA PHARMA AB (publ) höll på torsdagen den 29 april 2025 årsstämma hos MAQS Advokatbyrå, Gibraltargatan 7 i Malmö. Följande huvudsakliga beslut fattades:Fastställande av resulta...
PILA PHARMA UPCOMING INVESTOR MEETINGS
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites investors and others with interest in the Company, to meet PILA PHARMA at these upcoming events:
Malmömorgon (Slagthuset, Mal...
PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING
PILA PHARMA AB (publ) (FN STO: PILA) today reminds shareholders that today, 23 April is the last day to register attendance at this year's Annual General meeting.
PILA PHARMA wel...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdag den 29 april 2025, kl. 15.00 i MAQS Advokatbyrås loka...
REG
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024
PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-informa...
REG
PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024)
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2024.
The report can be found on the Company's website: https...
PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled H2 Report event in the coming week:
___________Stokk.io Online Webinar -...
REG
MAR
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (t...
PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the appointment of Hampus Darrell as new CFO.
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Researc...
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()